News

Video

Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: A report from the zanubrutinib extension study

Dr. Shirley D’Sa highlights the 5.8-year follow-up results from the ASPEN long-term extension study, demonstrating the durable efficacy, deepening responses, and favorable safety profile of zanubrutinib in patients with Waldenström macroglobulinemia, including those with high-risk genetic mutations.

Related Videos
CDAC CLL
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Phase 3 AMPLIFY Trial
BOVen
RMC-6236
Data from an Ongoing Phase 1/1b Study BGB-11417-101
Preliminary Results from the IMMagine-1 Trial
Related Content